

Shionogi Announces Appointment of Directors and Corporate Officers

Osaka, Japan, March 12, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that the Board of Directors Meeting held today informally decided the appointment of Directors, which will be officially announced at the 147th Annual General Meeting of Shareholders, scheduled to be held in June, 2012. Shionogi also announced the appointment of Corporate Officers and personnel change as of April 1, 2012.

1. Appointment of Candidates for Director

Candidates for Director (Scheduled in June, 2012)

Members of the Board	Name	Present position
Chairman of the Board, Representative Director	Motozo Shiono	(Reappointed)
Chief Executive Officer, Representative Director	Isao Teshirogi	(Reappointed)
Outside Director	Akio Nomura	(Reappointed)
Outside Director	Teppei Mogi	(Reappointed)
Outside Director	Katsuhiko Machida	(Newly-appointed) Chairman, Sharp Corporation

* Current Director Yasuhiro Mino will retire on the day of the Annual General Meeting of Shareholders.

* Representative Directors and other Directors are planned to be appointed at the Board of Directors Meeting. It is scheduled to be held on the same day as the Annual General Meeting of Shareholders.

2. Appointment of Corporate Officer (Effective; April 1, 2012)

New	Name	Present position
Corporate Officer, Executive General Manager, Human Health Care Division	Akio Tsubokura	Executive General Manager, Human Health Care Division
Corporate Officer, Executive General Manager, Overseas Business Division	Masaaki Takeyasu	Executive General Manager, Overseas Business Division

* Current Vice President Officer Yasuhiro Mino will retire on March 31, 2012.

3. Personnel Change (Effective; April 1, 2012)

New	Name	Present position
General Manager, Clinical Manufacturing Unit	Makoto Kobayashi	Deputy General Manager, Chemical Development Center

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596